Wire · opportunities
CEO O'Day tells Fierce how Gilead's cancer, inflammation expansion has reached 'critical mass'
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 September 2026 · Fusion42 review
Gilead Sciences CEO Daniel O'Day shared that the company has reached critical mass in its expansion into oncology and inflammation through a series of strategic acquisitions and increased R&D investment. The company is building its portfolio around cell therapy and inflammation drugs while investing $32 billion in U.S. research and manufacturing facilities.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a biotech sector where Gilead’s strategic biotech acquisitions have set a foundation few can replicate this year. Adjust your focus towards partnerships or innovations that complement cell therapy and inflammation portfolios to find openings.
◆ Coverage
1 source · 16 Sep 2026
◆ Related on Wire
◆ Topics